KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.
Saved in:
| Title: | KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. |
|---|---|
| Authors: | Mizrak Kaya, Dilsa1,2 (AUTHOR), Ma, Yangruijue2,3 (AUTHOR), Demir, Tarik1,3,4 (AUTHOR), Altomare, Nicole J.4,5 (AUTHOR), Kalyan, Aparna1,5 (AUTHOR), Kircher, Sheetal1,5 (AUTHOR), Mulcahy, Mary2,5 (AUTHOR), Benson III, Al B.3,5 (AUTHOR), Chen, Ruohui3,4 (AUTHOR), Mahalingam, Devalingam1,5 (AUTHOR) mahalingam@nm.org |
| Source: | Cancers. Jul2026, Vol. 18 Issue 13, p2037. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
